Kodiak Sciences Incis A Clinical Stage Biopharmaceutical Company Based In Palo Altocaliforniafounded In 2009The Company Specializes In Developing Innovative Therapeutics For Chronic Retinal Diseasesincluding Age Related Macular Degenerationamdand Diabetic Eye Diseaseskodiak Is Dedicated To Preventing And Treating Leading Causes Of Blindness Through Its Focused Approach In Ophthalmology The Company S Pipeline Features Several Promising Candidatesincluding Tarcocimab Tedromeran Anti Vegf Antibody Biopolymer Conjugate Designed For Extended Durability In Treating Retinal Vascular Diseasesksi 501 Is A Bispecific Antibody Biopolymer That Targets Both Il 6 And Vegf To Address Inflammation And Vascular Leakagewhile Ksi 10 Is An Unconjugated Bispecific Protein Aimed At Patients With Retinal Fluid Accumulationkodiak S Proprietary Antibody Biopolymer Conjugate Platform Enhances Treatment Durability And Reduces Dosing Frequency Compared To Existing Therapieskodiak Is Committed To Improving Patient Outcomes And Advancing Scientific Innovation In Retinal Therapeutics
No conferences found for this company.
| Company Name | Kodiak Sciences Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
